Ventas (VTR) AI Stock Analysis

• Market Cap: $37.47B
• Dividend Yield: 2.45%
• Average Volume (3M): 3.07M
• Price to Earnings (P/E): 147.2
• Beta (1Y): 0.27
• Revenue Growth: 15.69%
• EPS Growth: N/A
• Country: US
• Employees: 498
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Healthcare Facilities
• EPS (TTM): 0.14
• Shares Outstanding: 469,732,820
• 10 Day Avg. Volume: 3,281,253
• 30 Day Avg. Volume: 3,065,657
• PEG Ratio: -1.00
• Price to Book (P/B): 2.25
• Price to Sales (P/S): 4.92
• P/FCF Ratio: 33.41
• Enterprise Value/Market Cap: 1.21
• Enterprise Value/Revenue: 8.18
• Enterprise Value/Gross Profit: 19.50
• Enterprise Value/Ebitda: 21.16
• 1Y Price Target: $82.91
• Price Target Upside: 6.49% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: $80.00 ▲(2.75% Upside)

Ventas receives a solid overall score driven by strong earnings call performance and positive technical indicators. However, the high P/E ratio raises valuation concerns, and financial performance is moderate due to declining profit margins and low return on equity. The company's strategic focus on senior housing and improved leverage are positive factors.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Ventas' healthcare properties, enhancing long-term financial stability and shareholder value.

Senior Housing Investments

Increased investment in senior housing with attractive returns positions Ventas for sustained growth, capitalizing on demographic trends like aging population.

Cash Flow Management

Effective cash flow management ensures Ventas can fund operations and investments, supporting long-term strategic initiatives and financial health.

Negative Factors

Rising Debt Levels

High leverage may limit financial flexibility and increase risk, potentially impacting Ventas' ability to invest in growth opportunities.

Post-Acute Asset Dispositions

Dispositions of nonstrategic assets may reduce FFO, impacting short-term financial performance and potentially slowing growth momentum.

Competitive Acquisition Market

Increased competition in acquisitions could pressure Ventas' ability to secure favorable deals, impacting long-term growth and profitability.

Ventas Business Overview & Revenue Model

Company Description

Ventas, Inc. (VTR) is a real estate investment trust (REIT) that primarily invests in the healthcare sector, focusing on senior housing and healthcare properties. The company's portfolio includes a diverse range of assets such as independent living, assisted living, skilled nursing facilities, and medical office buildings. Ventas is committed to providing high-quality healthcare solutions and generating stable income through its extensive network of partnerships with leading operators in the healthcare industry.

How the Company Makes Money

Ventas generates revenue primarily through rental income from its properties, as it leases its healthcare facilities to various operators and healthcare providers. The company's revenue model is based on long-term leases, often with built-in rent escalations, which provide a steady cash flow. Additionally, Ventas may earn revenue from property sales and management fees associated with its portfolio. Key partnerships with established healthcare operators and a focus on acquiring high-quality, strategically located properties contribute significantly to its earnings. The company also benefits from demographic trends such as an aging population, which drives demand for healthcare and senior living services.

Ventas Financial Statement Overview

Summary

Ventas demonstrates moderate financial health with steady revenue growth and improved cash flow generation. However, declining profit margins and low return on equity highlight challenges in profitability and shareholder returns. The company's leverage is improving, but operational efficiency needs attention.

Income Statement

Ventas shows a moderate revenue growth rate of 4.77% TTM, indicating a steady increase in sales. However, the gross profit margin has significantly decreased to 15.46% TTM from 42.59% in the previous year, suggesting increased costs or pricing pressures. The net profit margin is low at 1.02% TTM, reflecting limited profitability. EBIT and EBITDA margins have also declined, indicating reduced operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has improved to 1.03 TTM from 1.28 in the previous year, showing better leverage management. However, the return on equity is low at 0.49% TTM, indicating limited returns for shareholders. The equity ratio is stable, suggesting a balanced capital structure.

Cash Flow

Free cash flow growth is positive at 7.42% TTM, indicating improved cash generation. The operating cash flow to net income ratio is not available, but the free cash flow to net income ratio is strong at 74.40% TTM, suggesting effective cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.56B	4.92B	4.50B	4.13B	3.83B	3.80B
Gross Profit	2.33B	2.10B	1.94B	1.85B	1.74B	1.86B
EBITDA	2.15B	1.94B	1.95B	1.62B	1.72B	1.94B
Net Income	238.01M	81.15M	-40.97M	-47.45M	49.01M	439.15M
Balance Sheet
Total Assets	26.93B	26.19B	24.73B	24.16B	24.72B	23.93B
Cash, Cash Equivalents and Short-Term Investments	188.62M	897.85M	508.79M	122.56M	149.72M	650.88M
Total Debt	12.79B	13.74B	13.69B	12.49B	12.22B	12.11B
Total Liabilities	14.50B	15.36B	15.18B	13.94B	13.77B	13.65B
Stockholders Equity	12.36B	10.77B	9.49B	10.15B	10.85B	10.18B
Cash Flow
Free Cash Flow	1.15B	725.78M	860.46M	666.09M	593.15M	921.53M
Operating Cash Flow	1.55B	1.33B	1.12B	1.12B	1.03B	1.45B
Investing Cash Flow	-3.80B	-2.38B	-184.66M	-859.22M	-724.14M	154.29M
Financing Cash Flow	1.33B	1.45B	-543.75M	-283.93M	-558.47M	-1.30B

Ventas Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 77.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTR, the sentiment is Positive. The current price of 77.86 is below the 20-day moving average (MA) of 79.51, above the 50-day MA of 74.79, and above the 200-day MA of 68.03, indicating a neutral trend. The MACD of 0.98 indicates Positive momentum. The RSI at 49.62 is Neutral, neither overbought nor oversold. The STOCH value of 18.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VTR.

Ventas Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WELL	77 Outperform	$128.16B	140.74	2.78%	1.51%	32.27%	67.00%
SBRA	77 Outperform	$4.78B	26.38	6.29%	6.26%	8.12%	75.95%
OHI	76 Outperform	$12.99B	24.70	11.28%	6.10%	13.50%	31.56%
VTR	68 Neutral	$37.47B	147.16	2.15%	2.45%	15.69%	―
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
DOC	58 Neutral	$11.80B	―	-0.48%	6.73%	9.58%	-111.99%
HR	56 Neutral	$6.04B	―	-7.26%	6.40%	-6.59%	33.35%

Ventas Corporate Events

Ventas Realty Issues $500M in Senior Notes

On December 4, 2025, Ventas Realty, a subsidiary of Ventas, Inc., successfully issued and sold $500 million in 5.000% Senior Notes due 2036. The proceeds from this offering are intended for general corporate purposes, including potential debt repayment, enhancing the company’s financial flexibility and operational capacity.

Ventas Announces Retirement of Key Executive

On November 17, 2025, Ventas, Inc. announced the planned retirement of Peter J. Bulgarelli, Executive Vice President of Outpatient Medical & Research and CEO of Lillibridge Healthcare Services, effective May 1, 2026. Bulgarelli has been pivotal in enhancing Ventas’s competitive edge and tenant satisfaction, and his departure will initiate a search for a successor to ensure a seamless transition, maintaining the company’s growth trajectory and industry leadership.